
Genentech, Inc. - Strategy, SWOT and Corporate Finance Report
Description
Genentech, Inc. - Strategy, SWOT and Corporate Finance Report
Summary
Genentech, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Genentech, Inc. (Genentech or ‘the company’), a subsidiary of Roche Group is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company’s medicines include Activase, Boniva Tablets, Cotellic, Erivedge, Fuzeon, Gazyva, Hemlibra, Invirase, Klonopin, Lucentis, Actemra, Nutropin AQ, Ocrevus, Tamiflu, Pegasys, Rituxan, Rocephin, Tecentriq, Polivy, Rozlytrek, Valium, Xeloda and Zelboraf. The company offers its products with a focus on the areas of oncology, immunology, neuroscience, metabolism, ophthalmology, and infectious disease. Genentech manages its manufacturing facilities and distribution center in California and Oregon, the US. The company is headquartered in South San Francisco, California, the US.
Scope
- Detailed information on Genentech, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Genentech, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Genentech, Inc. including a breakdown and examination of key business segments
- Intelligence on Genentech, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Genentech, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
- Gain understanding of Genentech, Inc. and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Genentech, Inc. as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Genentech, Inc.'s business structure, strategy and prospects.
Table of Contents
39 Pages
- Company Snapshot
- Generali France SA: Company Overview
- Generali France SA: Overview and Key Facts
- Generali France SA: Overview
- Generali France SA: Key Facts
- Generali France SA: Key Employees
- Generali France SA: Key Employee Biographies
- Generali France SA: Major Products and Services
- Generali France SA: Key Competitors
- Generali France SA: Company Analysis
- Generali France SA: Business Description
- Generali France SA: SWOT Analysis
- Generali France SA: SWOT Overview
- Generali France SA: Strengths
- Generali France SA: Weaknesses
- Generali France SA: Opportunities
- Generali France SA: Threats
- Generali France SA: Corporate Financial Deals Activity
- Generali France SA: Financial Deals Overview
- Generali France SA: Top Deals 2019 - 2023YTD*
- Generali France SA: Partnership
- Generali France SA: Recent Developments
- Generali France SA: News and Events Summary
- Generali France SA: Corporate Governance
- Generali France SA: Financial Deals
- Appendix
- Contact Us
- Methodology
- About MarketLine
- List of Tables
- Table 1: Generali France SA: Key Facts
- Table 2: Generali France SA: Key Employees
- Table 3: Generali France SA: Key Competitors
- Table 4: Generali France SA: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
- Table 5: Generali France SA: Top Deals 2019 - 2023YTD*
- Table 6: Generali France SA: Partnership Volume and Value Trend (2019 - YTD*2023)
- Table 7: Generali France SA: Partnership Trend by Deal Type (2019 - YTD*2023)
- Table 8: Generali France SA: News and Events Summary
- Table 9: Generali France SA: Corporate Governance
- Table 10: Generali France SA: Financial Deals
- List of Figures
- Figure 1: Generali France SA: Deal Activity by Deal Type - Volume (2019 - YTD*2023)
- Figure 2: Generali France SA: Partnership Volume and Value Trend (2019 - YTD*2023)
- Figure 3: Generali France SA: Partnership Trend by Deal Type (2019 - YTD*2023)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.